B+
Bull case
0%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
IMNM
ImmunomeDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$19.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+68.1
Score
AI commentary
The September 30 IND clearance adds a confirmed pipeline milestone, but the packet does not establish its sustained share-price effect. Analyst revisions, options skew, short interest, employee sentiment and sufficient social coverage are unavailable; sentiment zeros are placeholders, not measured neutral readings. The deterministic prior remains negative, so this is an event-driven monitoring view rather than a strong bullish call.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventIM-1340 Phase 1 initiationMedium impact
Immunome announced FDA IND clearance for its IM-1340 antibody-drug conjugate on September 30 and expects to begin a first-in-human solid-tumor study in Q4 2026. Clearance permits clinical testing; the reported antitumor activity is preclinical, not evidence of patient benefit. [#IR-2026-09-30] https://investors.immunome.com/immunome-announces-ind-clearance-for-im-1340-a-potential-first-in-class-antibody-drug-conjugate-for-the-treatment-of-solid-tumors/
2026-12-31eventEuropean varegacestat submissionMedium impact
Immunome plans to submit a varegacestat marketing application in Europe by year-end 2026. Submission would demonstrate execution, not constitute approval. [#8-K-2026-08-11] [#SEC-8K-2026-08-11]
2026-12-31catalystInitial IM-1021 lymphoma dataHigh impact
Immunome expects initial Phase 1 lymphoma data in 2026 and has reported objective responses at multiple dose levels. Response durability, safety and breadth remain to be established. [#SEC-8K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology